GlassScriptPhysician profile
Sylvester Mcrae
NPI 1790851699
$4,199.37
in general payments reported to CMS, 2019-2025
31 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $74.43 · 2021: $929 · 2022: $388 · 2023: $836 · 2024: $458 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.66 |
| Education | $265.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.07 | 2019-2025 | |
| Intuitive Surgical, INC. | $664.71 | 2019-2022 | |
| Astellas Pharma US INC | $566.00 | 2022-2024 | Veozah, Myrbetriq |
| Asensus Surgical, INC. | $452.12 | 2019 | |
| Sumitomo Pharma America, INC. | $276.04 | 2023-2025 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $207.50 | 2019-2023 | Aptima |
| Myovant Sciences INC. | $154.72 | 2021-2022 | |
| Pfizer INC. | $152.29 | 2022-2025 | |
| Biogen, INC. | $146.82 | 2025 | Zurzuvae |
| Lupin INC. | $143.87 | 2019 | |
| Myriad Women'S Health, INC. | $127.28 | 2023 | Myrisk |
| Coopersurgical, INC. | $84.96 | 2019-2024 | Paragard T 380a, Summit Doppler |
| Dexcom, INC. | $83.62 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $58.85 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.87 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $36.45 | 2020-2021 | |
| Organon LLC | $34.01 | 2024 | |
| Mylan Pharmaceuticals INC. | $30.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.80 | 2022 | |
| Mimedx Group, INC. | $26.29 | 2025 | |
| Shield Therapeutics INC | $24.44 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $23.95 | 2019 | |
| Optumhealth Care Solutions, LLC | $19.03 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Evofem Biosciences, INC. | $15.75 | 2021 | |
| Minerva Surgical, INC | $14.59 | 2019 | |
| Exeltis, USA INC. | $13.91 | 2025 | Slynd |
| Currax Pharmaceuticals LLC | $13.74 | 2025 | Contrave, Onzetra Xsail |
| Allergan, INC. | $13.07 | 2019 | |
| Covidien LP | $13.07 | 2019 | |
| Baxter Healthcare | $12.40 | 2022 | |
| Meditrina | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvester Mcrae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.